参考文献
参考文献
[1]Asrar A M,Dralands L,Missotten L,et al.Expression of apoptosis markers in the retinas of human subjects with diabetes[J].Invest Ophthalmol Vis Sci,2004,23(8):2760-2766.
[2]Krachmer J H.Cornea and External Disease:Clinical Diagnosis and Management.London,Mosby,1997.
[3]American Academy of Ophthalmology.External Disease and Cornea.Scetion 8,2005-2006.
[4]Krachmer JH.Cornea and External Disease:Clinical Diagnosis and Management.London,Mosby,1997.
[5]Komai Y,Ushiki T.The there-dimensional organization of collagen fibrils in the human cornea and sclera[J].Invest Ophthalmol Vis Sci,1991,12(32):2244.
[6]Friedberg M L,Pleyer U,Mondino BJ.Device drug delivery to the eye:collagen shields,iontophoresis,and pumps[J].Ophthalmology,1991,98(3):725.
[7]Stern G A,Buttross M.Useofcorticosteroids in combination with antimicrobial drugsin the treament ofinfectious cornealdisease[J].Ophthalmology,1991,98(12):847.
[8]Benson W H,Lanier J D.Comparison of techniques for culturing corneal ulcers[J].Ophthalmology,1992,99(3):800.
[9]Liesegang T J.Biology and molecular aspects of herpes simplex and varicellazoster virus infections[J].Ophthalmology,1992,99(4):781.
[10]Chew S J,et al.Early diagnosis of infectious keratitis with in vivo real time confocal microscopy[J].CLAO J,1992,18(9):197-201.
[11]Kato K D,Kurosaka T,Nagamoto.Apoptotic cell death in rabbit lens after lens extraetion[J].Invest OPhthalmol Vis Sci,1997,38(12):2322-2330.
[12]Lee J H.TGF-beta induced apoptosis and reduction of bcl-2 in human lens epithelial cell[J].CurrEyeRes,2002,25(11):147-153.
[13]Ishizaki Y.Control of lens epithelial cell survival.J Cell Biol,1993,121(12):899-908.
[14]Meacoek W R,SPalton M R,Stanford.Role of cytokines in the Pathogenesis of Posterior capsule opacification[J].Br J OPhthalmol,2000,84(3):332-336.
[15]Geissler E T,Li D W,James E R.Inhibition of lens epithelial cell growth by induction of apoptosis:Potential for prevention of posterior capsule opacification[J].J Ocul Pharmacol Ther,2001,17(5):587-596.
[16]Bacon A S.Acanthamoeba keratitis the value of early diagnosis[J].Ophthalmology,1993,100(7):1238.
[17]Larkin D.Treatment of Acanthamoeba keratitis with polyhexamethy lenbiguanide[J].Oph thalmology,1992,99(9):185.
[18]Mondino B M.Inflammatory diseases of the peripheral cornea[J].Ophthalmology,1988,95(2):643.(https://www.daowen.com)
[19]Wang Z,Chen J Q,Zheng H L.An immunohistochemical study of cornea and adjacent bulbar conjunctiva in Mooren’s ulcer[J].Chinese J Ophthalmol,1994,30(9):218.
[20]Kinoshita S.Long-term results of keratoepithelioplasty in Mooren’s ulcer[J].Ophthalmology,1991,98(7):438.
[21]Street DA.Lack of association between keratoconus,mitral valve prolapse,and joint hypermobility[J].Ophthalmology,1991,98(12):170.
[22]Swartz N.Personality and keratoconus[J].CLAO,1990,16(11):62-64.
[23]Shimmura S,Kazuo T.Ocular surface reconstruction update[J].Current Opinion in Ophthalmology,2002,13(1):213-219.
[24]Siddiqui N,Afshari N A.The changing face of the genetics of corneal dystrophies[J].Current Opinion in Ophthalmology,2002,13(12):199-203.
[25]Moorthy R S,Inomata H,Rao N.Vogt-Koyanagi-Harada syndrome[J].Surv Ophthalmol,1995,39(1):1195-1198.
[26]Recchia F M,Brown G C.Systemic disorders associated with retinal vascular occlusion[J].Curr Opin Ophthalmol,2000,11(2):462-467.
[27]Kanski J J,Mileweki S A.Diseases of the Macula:A clinical Approach,St.Louis,Mosby,2002.
[28]The Collaborative Normal-Tension Glaucoma Intervention Study Group.The effectiveness of intraocular pressure reduction in the treatment of normaltension glaucoma[J].Am J Ophthalmol,1998,126(1):498-505.
[29]Yang P,Fang W,Jin H,et al.Clinical features of Chinese patients with Fuchs syndrome[J].Ophthalmology,2006,113(5):478-485.
[30]Yang P,Ren Y,Li B,et al.Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients[J].Ophthalmology,2007,114(8):606-614.
[31]Yang P,Zhang Z,Zhou H,et al.Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China[J].Curr Eye Res,2005,30(9):943-948.
[32]Feiner L,Piltz-Seymour J R.Collaborative Initial Glaucoma Treatment Study:a summary of results to date[J].Curr Opin Ophthalmol,2003,14(4):106-111.
[33]Foster PJ,Buhrmann R,Quigley HA,et al.The definition and classification of glaucoma in prevalence surveys[J].Br J Ophthalmol,2002,86(10):238-242.
[34]Heijl A,Leske M C,Bengtsson B,et al.Reduction of intraocular pressure and glaucoma progression:results from the Early Manifest Glaucoma Trial[J].Arch Ophthalmol,2002,120(9):1268-1279.
[35]Kass M A,Heuer D K,Higginbotham E J,et al.The ocular hypertension treatment study[J].Arch Ophthalmol,2002,12(4):701-713.
[36]Schwartz P S,Hockenbery D M.Bcl-2related survival proteins[J].CellDeath Differ,2006,13(8):1250.